Smith & Nephew plc reports news as a global medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. Coverage centers on Orthopaedics, Sports Medicine & ENT and Advanced Wound Management, including wound dressings, negative pressure wound therapy, cartilage and rotator cuff repair implants, orthopedic reconstruction, trauma and extremities products, and surgical robotics.
Recurring developments include product launches and clinical evidence for ALLEVYN COMPLETE CARE, RENASYS EDGE, CARTIHEAL AGILI-C, REGENETEN, CORI, AETOS and related platforms; conference showcases; distribution agreements; segment performance updates; share buybacks; and governance matters tied to the company’s London-listed shares and NYSE-traded ADRs.
On July 28, 2020, Smith+Nephew (NYSE: SNN) launched the RI.HIP NAVIGATION technology for total hip arthroplasty (THA). This system enhances surgical accuracy through patient-specific component alignment, following the acquisition of Brainlab's Orthopaedic Joint Reconstruction business in May 2019. The POLAR3™ Primary Total Hip System, known for delivering a 98% survivorship rate at 8 years, integrates with Brainlab's platform used in over 500 hospitals. This innovation received FDA clearance and CE Mark certification, aiming to improve patient outcomes while being cost-efficient for hospitals and ASCs.
Smith+Nephew (NYSE:SNN) announced a significant milestone with over two million patients treated using their OXINIUM Technology, a proprietary oxidized zirconium alloy for hip and knee replacements. OXINIUM offers a combination of metal strength and ceramic wear resistance, enhancing durability and performance in joint applications.
Clinical data highlights OXINIUM's superiority, including 29% reduction in revision risk post arthroplasty and results from 45 million cycles in wear testing. This technology underpins advanced products like POLAR3 and JOURNEY II, reflecting Smith+Nephew's commitment to innovation in orthopaedics.
Smith+Nephew (NYSE:SNN) announced on June 16, 2020, that its REGENETEN Bioinductive Implant has received CE Mark certification, allowing its use in key European markets. This implant has been pivotal in over 40,000 procedures in the US, enhancing approaches to rotator cuff surgery. The implant, which aids natural healing by promoting tendon-like tissue growth, will be available for over 310,000 annual rotator cuff procedures in Europe, a market worth approximately $175 million. The company aims to transform patient outcomes with this innovative technology.